Drug Trial Radar · NCT05330975
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age
Last checked: Nov 19, 2026Latest source record: Dec 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,317
Actual
Start
Apr 1, 2022
Primary completion
Nov 8, 2024
Study completion Nov 8, 2024
Sponsor
- Lead sponsor
- ModernaTX, Inc.Moderna (MRNA)
- Sponsor type
- Industry
- First posted
- Apr 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purposes of Part A of this study are to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 coadministered with a seasonal influenza vaccine (Afluria® Quadrivalent); to evaluate the impact of coadministered influenza vaccine on the immune response to RSV-A; and to evaluate the impact of coadministered RSV vaccine on the immune response to influenza. The main purposes of Part B of this study are to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 coadministered with mRNA-1273.214; to evaluate the effect of coadministered mRNA-1273.214 on the immune response to RSV-A; and to evaluate the effect of coadministered RSV vaccine on the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The main purposes of Part C (single arm, open-label) of this study are to evaluate the safety and tolerability of a booster dose (BD) of mRNA-1345 administered at 1 Year following a primary dose; to evaluate the immune response to RSV-A of a BD of mRNA 1345 administered at 1 Year following a primary dose; and to evaluate the immune response to RSV-B of a BD of mRNA-1345 administered at 1 Year following a primary dose.
Conditions
- Respiratory Syncytial Virus
Interventions
PlaceboBiological
0.9% sodium chloride (normal saline) injection
mRNA-1345Biological
Sterile liquid for injection
Afluria® QuadrivalentBiological
single-dose, pre-filled syringe for injection
mRNA-1273.214Biological
Sterile liquid for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 InjectionTime frame: Within 7 days after Day 1 injection
- Part A: Number of Participants With Unsolicited Adverse Events (AEs) After Day 1 InjectionTime frame: Day 1 through Day 28 (28 days after Day 1 injection)
- Part A: Number of Participants With Medically Attended AEs (MAAEs), SAEs, Adverse Events of Special Interest (AESIs), and AEs Leading to WithdrawalTime frame: Day 1 through Day 181 (end of Study Part A)
- Part A: Geometric Mean Titer (GMT) of Serum Respiratory Syncytial Virus Subtype A (RSV-A) Neutralizing Antibodies (NAbs) at Day 29Time frame: Day 29
- Part A: Percentage of Participants With Seroresponse in RSV-A NAbs at Day 29Time frame: Day 29
- Part A: GMT of Serum Anti-hemagglutination (HA) Ab Level, as Measured by Hemagglutination Inhibition (HAI) Assay for Influenza at Day 29Time frame: Day 29
- Part B: Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 1 InjectionTime frame: Within 7 days after Day 1 injection
- Part B: Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 29 InjectionTime frame: Within 7 days after Day 29 injection
- Part B: Number of Participants With Unsolicited AEs After Day 1 InjectionTime frame: Day 1 through Day 28 (28 days after Day 1 injection)
- Part B: Number of Participants With Unsolicited AEs After Day 29 InjectionTime frame: Day 29 through Day 57 (28 days after Day 29 injection)
- Part B: Number of Participants With MAAEs, SAEs, AESIs, and AEs Leading to WithdrawalTime frame: Day 1 through Day 211
- Part B: GMT of Serum RSV-A at Day 29Time frame: Day 29
- Part B: Percentage of Participants With Seroresponse for RSV-A Neutralizing Abs From Baseline to Day 29Time frame: Baseline to Day 29
- Part B: Geometric Mean Concentration (GMC) of Serum Ab Level, as Measured by Neutralization Assay for SARS-Cov-2 at Day 29Time frame: Day 29
- Part B: Percentage of Participants With Seroresponse for SARS-Cov-2 NAbs From Baseline to Day 29Time frame: Baseline to Day 29
- Part C: Number of Participants With Solicited Local and Systemic Within 7 Days After Revaccination Day 1Time frame: Within 7 days after Day 1 revaccination
- Part C: Number of Participants With Unsolicited AEs Within 28 Days After Revaccination Day 1Time frame: Revaccination Day 1 through Day 28 (28 days after revaccination Day 1)
- Part C: Number of Participants With MAAEsTime frame: Revaccination Day 1 through Day 181
- Part C: Number of Participants With SAEs, AESIs, and AEs Leading to WithdrawalTime frame: Revaccination Day 1 through Day 361
- Part C: GMT of Serum RSV-A and RSV-B NAbs mRNA-1345 Revaccination Day 29 Compared to Primary Vaccination Day 29Time frame: Primary Vaccination Day 29 to Revaccination Day 29
Locations
62 sites in 1 country. Site status is shown where the registry gives one.
Central Research Associates Inc
Birmingham, Alabama
Del Sol Research Management - Clinedge - PPDS
Tucson, Arizona
Paragon Rx Clinical, Inc
Garden Grove, California
Ark Clinical Research
Long Beach, California
Long Beach Clinical Trials, LLC (Site 1)
Long Beach, California
Long Beach Clinical Trials, LLC (Site 2)
Long Beach, California
Central Valley Research, LLC
Modesto, California
Velocity Clinical Research - Panorama City
Panorama City, California
Empire Clinical Research
Pomona, California
Acclaim Clinical Research
San Diego, California
Medical Center For Clinical Research - M3 WR - ERN - PPDS
San Diego, California
Ark Clinical Research
Tustin, California
Chase Medical Research LLC
Waterbury, Connecticut
Teradan Clinical Trials
Brandon, Florida
Revival Research Corporation - Clinedge - PPDS
Doral, Florida
Dolphin Medical Research
Doral, Florida
Indago Research and Health Center
Hialeah, Florida
Westside Center for Clinical Research - ERN - PPDS
Jacksonville, Florida
Suncoast Research Group LLC - ERN-PPDS
Miami, Florida
Suncoast Research Associates LLC - ERN - PPDS
Miami, Florida
Floridian Clinical Research - ClinEdge - PPDS
Miami Lakes, Florida
Tekton Research - Georgia - Platinum - PPDS
Chamblee, Georgia
Lifeline Primary Care / CCT Research
Lilburn, Georgia
Georgia Clinic / CCT Research
Norcross, Georgia
Meridian Clinical Research (Savannah Georgia) - Platinum - PPDS
Savannah, Georgia
East-West Medical Research Institute
Honolulu, Hawaii
Meridian Clinical Research (Sioux City - Iowa)
Sioux City, Iowa
Meridian Clinical Research, LLC (Overland Park, Kansas) - Platinum - PPDS
Overland Park, Kansas
Meridian Clinical Research (Baton Rouge-Louisiana) - Platinum - PPDS
Baton Rouge, Louisiana
Clinical Trials of SWLA, LLC
Lake Charles, Louisiana
Meridian Clinical Research (Rockville Maryland) - Platinum - PPDS
Rockville, Maryland
Clinical Research Institute, Inc - CRN - PPDS
Minneapolis, Minnesota
Meridian Clinical Research (Grand Island) - Platinum - PPDS
Grand Island, Nebraska
Meridian Clinical Research, LLC (Lincoln Nebraska) - Platinum - PPDS
Lincoln, Nebraska
Be Well Clinical Studies, LLC
Lincoln, Nebraska
Meridian Clinical Research
Norfolk, Nebraska
Meridian Clinical Research (Omaha-Nebraska) - Platinum - PPDS
Omaha, Nebraska
Midwest Regional Health Services - CCT Research
Omaha, Nebraska
Clinical Research Center of Nevada - ERN - PPDS
Las Vegas, Nevada
Santa Rosa Medical Centers of Nevada - CCT Research
Las Vegas, Nevada
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.